Mechanism of Thrombosis During COVID-19 Infection Due to SARS-CoV-2 Virus and its Variants, and a Clinically Proven Strategy to Combat with Probiotics and their Immunomodulins
Main Article Content
Abstract
The US patent 11,077,052 B1, issued in August of the year 2021, has been granted relying on the research conducted until September 2020, using the multiple mixed strain probiotics and their immunomodulins to prevent or treat COVID-19 due to SARS-CoV-2 and its limited variants. Since then the SARS-CoV-
2 virus continuously generated multiple variants with different genomic configurations, almost to the point of overriding the vaccines and medications. The objective of this research article is to evaluate the effectiveness of the invention outlined in the U.S. patent 11,077,052 B1 on the variants of SARS- CoV-2 evolved in the later years of 2020, 2021 and 2022. This research has great significance because vaccines are not totally effective because of the high rate of mutations of SARS-CoV-2 virus resulting in antigenically different variants, which are overriding the immunity conferred by vaccines. Thus, there is a definite need for a reliable alternative or adjuvant therapy, which can be used either by itself or used as adjuvant therapy along with vaccines to combat COVID-19 infection due to SAR-CoV-2 virus and its continuously mutating variants of different antigenicity. The results of this investigation proved that the use of multiple mixed strain probiotics along with their immunomodulins are effective not only on novel SARS-CoV-2 coronavirus evolved in late 2019 and mid 2020 but also the mutated variants in the later part of the years 2020, 2021, and 2022. The COVID-19 pandemic is not yet contained as of August 2022. The SARS-CoV- 2 virus has been continuously mutating generating variants which are resisting vaccines and the treatments. The death’s due to SARS -COV- 2 viral infections are attributed predominantly to cytokine storm and thrombosis resulting in ARDS (Acute Respiratory Disease Syndrome} and multi organ failure. The earlier published article thoroughly discussed about the genesis and control of cytokine storm to protect the victims. This article mainly emphasizes the Pathophysiology of thrombosis, due to SARS-CoV-2 virus and its recent multiple variants, and the ways and means of controlling it to prevent or cure COVID-19, using the multiple mixed strain probiotics and their Immunomodulins. The hormonal and enzymatic system variations causing the disturbance in homeostasis of the vascular system resulting in thrombosis, due to SARS-CoV-2 virus and its continuously evolving variants is thoroughly discussed. In addition, the infection pattern and progression of the SARS-CoV-2 virus causing endothelial cell lysis of the vascular system resulting in thrombosis has been elucidated with molecular details. The specific role of immunomodulins of the multiple mixed strain probiotics to prevent or treat COVID-19 disease induced thrombosis has also been presented. The physiological functions of individual components of the probiotics and the immunomodulins produced by the multiple mixed strain probiotics, is presented for the first time with explicitly proven molecular details, showing how they contribute individually and cumulatively to prevent or treat COVID-19 infection, due to SARS-CoV-2 virus and its multiple variants, generated during the years 2020 through 2022, to induce thrombosis.
Keywords:
Multiple Mixed Strain Probiotics, Probiotic Immunomodulins, Immunomodulins, Postbiotics, Thrombosis, COVID-19, SARS-CoV-2, Corona Virus, ACE-2, ACE, US Patent # 11,077,052, Lysosomal Trafficking Pathway, Biosynthetic Secretory Pathway, Delta variant, Omicron Variant, Dysbiosis
Article Details
How to Cite
REDDY, Malireddy S..
Mechanism of Thrombosis During COVID-19 Infection Due to SARS-CoV-2 Virus and its Variants, and a Clinically Proven Strategy to Combat with Probiotics and their Immunomodulins.
Medical Research Archives, [S.l.], v. 10, n. 9, sep. 2022.
ISSN 2375-1924.
Available at: <https://esmed.org/MRA/mra/article/view/3075>. Date accessed: 21 nov. 2024.
doi: https://doi.org/10.18103/mra.v10i9.3075.
Section
Research Articles
The Medical Research Archives grants authors the right to publish and reproduce the unrevised contribution in whole or in part at any time and in any form for any scholarly non-commercial purpose with the condition that all publications of the contribution include a full citation to the journal as published by the Medical Research Archives.
References
1. Porcheddu, R., Serra, C., Kelvin, D., et.al. Kelvin, N., Similarity in Case Fatality Rates (CFR) of COVID-19/SARS-COV-2 in Italy and China. J. Infect. Dev. Ctries. 2020; 14: 125–128. doi: 10.3855/jidc.12600
2. Reddy MS. Mechanism of Cytokine Storm in COVID-19: How can probiotics combat it? JAAPI. 2021; 1(3): 27-35.
3. Reddy MS. Selected multiphase treatment for coronavirus respiratory infections. US Patent #11,077,052, B1. 2021; 1-38.
4. Li, W., Moore, M. J., Vasilieva, N. et al. Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature. 2003; 426: 450–454. doi: 10.1038/nature02145
5. Li X, Jang Y, Agostin IS, et. al. Is Hydrochloroquine beneficial for Covid -19 patients? Cell Death Dis. 2020; 11: 512. https://doi.org/10.1038/s41419-020-2721-8.
6. Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell 2020; 181: 271–280. doi: 10.1016/j.cell.2020.02.052
7. Kirchdoerfer RN, Cottrell CA, Wang, N, et al. Pre-fusion structure of a human coronavirus spike protein. Nature. 2016; 531: 118–121. doi: 10.1038/nature17200
8. Turner, A. J., Tipnis, S. R., Guy, J. L., et. al. ACEH/ACE2 is a novel mammalian metallocarboxypeptidase and a homologue of angiotensin-converting enzyme insensitive to ACE inhibitors. Can. J. Physiol. Pharmacol. 2002; 80: 346–353. doi: 10.1139/y02-021
9. Yan, R., Zhang, Y., Li, Y., et. Al. Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2. Science. 2020; 367: 1444–1448. doi: 10.1126/science.abb2762
10. Sharma A, Sharma SK, Shi Y, et.al. BCG Vaccination Policy and preventive Chloroquine usage: Do they have an impact on covid -19 pandemic? Cell Death Dis. 2020; 11: 516. https://doi.org/10.1038/s41419-020-2720-9.
11. Verkhratsky A, Li Q, Melino S, et.al. Can COVID -19 pandemic boost the epidemic of Neurogenerative disease? Biol. 2020; Direct 15: 28.
12. Donoghue M, Hsieh F, Baronas E, et al. A novel angiotensin-converting enzyme–related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9. Circul. 2000; Res. 87, e1–e9. doi: 10.1161/01.RES.87.5.e1
13. Celardo I, Pace L, Cifaldi L,. et.al. The immune system view of the Corona Virus SARS – CoV-2. Biol Direct. 2020; 15:30.
14. Krijnse-Locker J, Ericsson M, Rottier P. Characterization of the budding compartment of mouse hepatitis virus: evidence that transport from the RER to the Golgi complex requires only one vesicular transport step. J. Cell Biol. 1994; 124: 55–70. doi: 10.1083/jcb.124.1.55
15. Ghosh S, Dellibovi – Raghes TA, Kerviel A, et.al., β – Coronaviruses use lysosomes for egress instead of the biosynthetic secretory pathway. Cell. 2020; 183(6): 1520-1535.
16. Fehr AR, and Perlman S. Coronaviruses: an overview of their replication and pathogenesis. Coronaviruses. 2015; 1282: 1–23. doi: 10.1007/978-1-4939-2438-7_1
17. Ducatelle R, Hoorens, J. Significance of Lysosomes in the Morphogenesis of Corona Viruses. Arch Viral. 1984; 79: 1-12.
18. Westerbeck JW, Machamer CE. The infectious Bronchitis Corona Virus envelop protein alters Golgi Ph to protect the spike protein and promote the release of infectious virus. J. Virol. 2019; 93: (11): e.000 15-19. Doi: 10. 1128/jvi. 0015-19.
19. Matsuyama MA, Kubil SP, Yoshinaga SK, et al. An Aberrant Stat pathway is central to COVID -19. Cell Death Differ. 2020; 27: 3209-3225.
20. Wang X, Melino G, Shi Y. Active or passively deacidified Lysosomes push β – Corona Virus egress. Cell Death Disease. 2021; 12:235.
21. Agarti C, Sacchi A, Bordoni V, et.al. Expansion of Myeloid derived suppressor cells in patients with severe Corona Virus disease (COVID -19). Cell Death Differ. 2020; 3196 – 3207.
22. Shi Y, Wang Y, Shao C, et.al. COVID -19 infection: The perspective on immune responses. Cell Death Differ. 2020; 27: 1451-1454.
23. Reddy MS. Probiotics: genesis, current definition, and proven therapeutic properties. JAAPI. 2021; l (2): 18-26.
24. Expert consultation on evaluation of health and nutritional properties of probiotics in food including powdered milk with live lactic acid bacteria 2001 (Google scholar). http://www.fao.org/3/a0512e/aO512e.pdf
25. Teame T, Wang A, Xie M, et al. Paraprobiotics and postbiotics of probiotic lactobacilli, their positive effects on the host action mechanism: A review. Front Nutr. 2020; 22: 1-56.
26. Lebeer S, Vanderleyden J, Dekeersmaechker. SCJ. Host interactions of probiotic bacterial surface molecules: comparison with commensals and pathogens. Nat Rev Microbiol 2010; 8: 171-184.
27. Asong J, Wolfert MA, Maiti KK, et al. Binding and cellular activation studies reveal that toll-like receptor-2 can differentially recognize peptidoglycan from gram- positive and gram-negative bacteria. J Biol Chem. 2009; 284: 8643-8653.
28. Shida K, Kiyoshima – Shibata J, Kaji R, et al. Peptidoglycan from lactobacilli inhibits interleukins-12 production by macrophages indued by Lactobacillus casei through toll-like receptor-2 dependent and independent mechanisms. Immunol. 2009; 128: 858-869.
29. Fernandez EM, Valenti R, Rockel C, et al. Anti-inflammatory capacity of selected lactobacilli in experimental colitis is driven by NOD-2-mediated recognition of specific peptidoglycan-derived muropeptide. Gut. 2011; 60: 1050-1059.
30. Noh SY, Kang SS, Yun CH, et al. Lipoteichoic acid from Lactobacillus plantarum inhibits PAM-2 CSK4-induced IL-8 production in human epithelial cells. Mol Immunol. 2015; 64: 183-189.
31. Bleau C, Monges A, Rashidan K, et al. Intermediate chains of exopolysaccharides from Lactobacillus rhamnosus RW-9595 M increases lL-10 production by macrophages. J Appl Microbiol. 2010; 108: 666-675.
32. Murofushi Y, Villena J, Morie K, et al. The toll-like receptor family protein RP105/MDl complex is involved in the immunoregulatory effect of exopolysaccharides from Lactobacillus plantarum N 14. Mol Immunol. 2015; 64: 63-75.
33. Makino S, Ikegami S, Kume A, et al. Reducing the risk of infection in the elderly by dietary intake of yogurt with Lactobacillus delbrueckii ssp. bulgaricus OL L 1073 R-l. Br J Nutr. 2010; 104: 998-1006.
34. Lebeer S, Claes l, Tytgat HLP, et al. Functional analysis of Lactobacillus rhamnosus GG pili in relation to adhesion and immunomodulatory interactions with intestinal epithelial cells. Appl Environ Microbiol. 2012; 78: 185-193.
35. Vargas Garcia CE, Petrova M, Claes IJJ, et al. Piliation of Lactobacillus rhamnosus GG promotes adhesion, Phagocytosis, and cytokine modulation in macrophages. Appl Environ Microbiol. 2015; 81: 2050-2062.
36. Seth A, Yan F, Polk DB, et al. Probiotics ameliorate the hydrogen peroxide -induced epithelial barrier disruption by a PKC-and MAP kinase-dependent mechanism. Am J Physiol Gastrointest liver physiol. 2008; 294: 1060-1070.
37. Herawati I, Hilmiprima D, Fauziah N, Effect of lactic acid filtrate and bacteriocins of Lactobacillus acidophilus on phagocytosis activity of macrophages cell against Enteropathogenic Escherichia coli (EPEC). Microbiol. 2014; 8: 183-190.
38. Pascale A, Marchesi N, Marelli C, et al. Microbiota and metabolic diseases. Endocrine 61: 1357-1371.
39. Smith PM, Howitt MR, Panikov N, et al. Microbial metabolites, short chain fatty acids, regulate colinic t-reg cell homeostasis. Science. 2013; 341: 569-573.
40. Furusawa Y, Yuuki Obata Y, Shinji Fukuda S, et al. Commensal microbiome derived butyrate induces the differentiation of colonic regulatory T-cells. Nature. 2013; 504: 446-450.
41. Roelofsen H, Priebe MG, Vonk RJ, et al. The interaction of short chain fatty acids with adipose tissue: Relevance for prevention of type 2 diabetes. Beneficial microbes. 2010; 1: 433-437.
42. Sun M, Wu W, Chen L, et al. Microbiota derived short chain fatty acids promote TH-l cell lL-10 production to maintain intestinal homeostasis. Nat Commun. 2018; 9: 3555.
43. Reddy MS. Pathophysiology of thrombosis in COVID-19: Possible remedy through Multiple-Mixed-Strain Probiotic Adjuvant therapy. Shusruta medical news AAPI Journal. 2020 https://www.aapiusa.org/wpcontent/uploads/2020/04/sushruta-med-news April 2020.pdf.
44. Baud D, Qi, X, Nielsen-Saines, K, et. al. Real estimates of mortality following COVID-19 infection. Lancet Infect. Dis. 2020. doi: 10.1016/S1473-3099(20)30195-X.
45. Crackower MA, Sarao R, Oudit GY, et al. Angiotensin-converting enzyme 2 is an essential regulator of heart function. Nature. 2002; 417, 822–828. doi: 10.1038/nature00786
46. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 395: 497–506, 2020. doi: 10.1016/S0140-6736(20)30183-5
47. Ramachandran, V., Ismail, P., Stanslas, J., et. al. Association of insertion/deletion polymorphism of angiotensin-converting enzyme gene with essential hypertension and type 2 diabetes mellitus in Malaysian subjects. J. Renin Angiotensin Aldosterone Syst 2008; 9: 208–214. doi: 10.1177/1470320308097499
48. Gustafsson F, and Holstein-Rathlou NH. Angiotensin II modulates conducted vasoconstriction to norepinephrine and local electrical stimulation in rat mesenteric arterioles. Cardiovasc. 1999; Res 44: 176–184. doi: 10.1016/S0008-6363(99)00174-1
49. Watanabe, T., Barker, T. A., and Berk, B. C. Angiotensin II and the endothelium: diverse signals and effects. Hypertension. 2005;45: 163–169. doi: 10.1161/01.HYP.0000153321.13792.b9
50. Senchenkova, E. Y., Russell, J., Almeida-Paula, L. D., et. Al. Angiotensin II–mediated microvascular thrombosis. Hypertension. 2010; 56: 1089–1095. doi: 10.1161/HYPERTENSIONAHA.110.158220
51. Santos, R. A., e Silva, A. C. S., Maric, C., et al. Angiotensin-(1-7) is an endogenous ligand for the G protein-coupled receptor Mas. Proc. Natl. Acad. Sci. U.S.A. 2003; 100: 8258–8263. doi: 10.1073/pnas.1432869100
52. Singh, K. D., and Karnik, S. S. Angiotensin receptors: structure, function, signaling and clinical applications. J. Cell Signal 2016; 1: 111. doi: 10.4172/jcs.1000111
53. Tay, K.-H., and Lip, G. Y. (2 What “Drives” the Link Between the Renin–Angiotensin–Aldosterone System and the Prothrombotic State in Hypertension? Oxford, UK: Oxford University Press, 2008.
54. Zhou, F., Yu, T., Du, R., et.al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020; 395: 1054–1062. doi: 10.1016/S0140-6736(20)30566-3
55. Liu Y, Yu X, Yu L et al. Lactobacillus plantarum CCFM 8610 alleviates irritable bowel syndrome and prevents gut microbiota dysbiosis: a randomized double blind, placebo-controlled pilot clinical trial. Engineering. 2021; 7(3): 376-385.
56. Salva S, Villena J, Alverez S. Immunomodulatory activity of Lactobacillus rhamnosus strain isolated from goat milk: Impact on intestinal and respiratory infections. Int J Food Microbiol. 2010; 141(1-2): 82-89.
57. Klaver FAM, Van der Meer R. The assumed estimation of cholesterol removal by lactobacilli and Bifidobacterium bifidum is due to their bile salt deconjugation activity. Appl Environ Microbiol. 1993; 59: 1120-1124.
58. Borchers AT, Selmi C, Meyers FJ et al. Probiotics and Immunity. J Gastroenterol. 2009; 44: 26-46. Doi:10.1007/s00535-008-2296-0.
59. Brashears MM, Gilliland SE, Buck LM. (1998). Bile salt deconjugation and cholesterol removal from media by Lactobacillus casei. J Dairy Sci. 1998; 81: 2103-2110.
60. Reddy MS. Dr. M.S. Reddy’s Multiple Mixed Strain Probiotic Adjuvant Cancer Therapy, to complement immune checkpoint therapy and other traditional cancer therapies, with least autoimmune side effects through eco-balance of human microbiome. Int J. Pharma Sci Nano Tech. 2018; 11(6): 4295-4317.
61. Sgouras D, Maragkoudakis P, Petraki K et al. In vitro and In vivo inhibition of Helicobacter pylori by Lactobacillus casei strain Shirota. Appl Environ Microbiol. 2004; 70: 518-526. Doi:10.1128/aem.70.1.518-526.
62. Chen Y, Li C, Xue J et al. Characterization of angiotensin-converting enzyme inhibitory activity of fermented milk produced by Lactobacillus helveticus. J Dairy Sci. 2015; 98(8): 5113-5124. https://doi.org/10.3168/jds. 2015-9382.
63. Yamamura S, Morishima H, Kumano-go T et al. The effect of Lactobacillus helveticus fermented milk on sleep and health perception in elderly subjects. Eur J Clinical Nutrition. 2009; 63(1): 100-105.
64. Hosoya T, Sakai F, Yamashita M et al. Lactobacillus helveticus SBT2171 inhibit lymphocyte proliferation by regulation of the JNK signaling pathway. Plos one. 2019; v9(9) e 108-360. https:// doi. Org/10.1371/journal.pone.0108360.
65. Huang R, Wang K, Hu J. Effect of probiotics on depression: A systematic review and meta-analysis of randomized controlled trials. Nutrients. 2016; 8(8): 483. https.//doi.org/10.3390/nu8080483.
66. Liang S, Wang T, Hu X et al. Administration of Lactobacillus helveticus NS8 improves behavioral, cognitive, and biochemical aberrations caused by chronic restraint stress. Neuroscience. 2015; 310: 561-577.
67. Saarela M, Lahteenmaki I, Crittenden R et at. Gut bacteria and health foods-the European perspective. Int J Food Microbiol. 2002; 78: 99-117.
68. Rodriguez C, Medici M, Valdez GF et al. Therapeutic effect of Streptococcus thermophilus CRL-1190-fermented milk on chronic gastritis. World J Gastroenterol. 2010; 16(13): 1622-1630. Doi: 10.3748/wig.v16.i13.1622.
69. Lecomte X, Gagnaire V, Lortal S et al. Streptococcus thermophilus, an emerging and pro liberation of bio peptides from milk for tool for heterologous expression: advantages and future trends. Food Microbiol. 2016; 53: 2-9. Doi: 10.1016/j.bk.2015.05.003.
70. Reddy MS and Reddy DRK. An insight into the 2016 Best Medical Award-Winning Breakthrough Microbial and Nanotechnology based discovery of Dr. M.S. Reddy’s Multiple Mixed Strain Probiotic Therapy, to successfully treat the Nosocomial infections. Nano Technol and Nano Sci. J. 2017; 1(1): 2-5.
71. Tufail M, Hussain S, Malik F et al. Isolation and evaluation of antimicrobial activity of bacteriocin produced by Lactobacillus bulgaricus from yogurt. AFR J Microbiol Res. 2011; 5: 3842-3847.
72. Vacchi ED and Drago L. Lactobacillus sporogenes or Bacillus coagulans; misidentification or mislabeling. Int J Probiotics. 2006; 1: 3-10.
73. Zhang M, Hang X, Fan X et al. Characterization and selection of lactobacillus strains for their effect on bile tolerance, taurocholate deconjugation and cholesterol removal. World J Microbiol Bio Technol. 2008; 24(1): 7-14. Doi.org/10.1007/s11274-007-9431-6.
74. Ahn YT, Kim GB, Lim KS et al. Deconjugation of bile salts by Lactobacillus acidophilus isolates. Int Dairy J. 2003; 13: 300-311.
75. Anderson JW and Gilliland SE. Effect of fermented milk (yogurt) containing lactobacillus acidophilus L1 on serum cholesterol in hypercholesterolemic humans. J AM College Nutr. 1999; 18: 43-50.
76. Nuryshev M, Stoyanova LLG and Netrusov AI. New probiotic culture of Lactococcus lactis ssp. lactis: Effective opportunities and prospects. J Micro Biochem Technol. 2016; 8: 290-295. Doi:10.4172/1948-5948.1000 299.
77. Darby TM, Owens JA, Saeedi BJ et al. Lactobacillus lactis subsp. cremoris is an efficacious beneficial bacterium that limits tissue injury in the intestine. Science. 2019; 12: 356-367. Doi:10.1016/j.IscI.2019.030.
78. Reddy MS and Reddy DRK. Development of Multiple Mixed Strain Probiotics for “Probiotic therapy” under clinical conditions, to prevent or cure the deadly hospital acquired infections due to Clostridium difficile (C. diff) and Methicillin Resistant Staphylococcus aureus (MRSA). Int J Pharma Sci Nanotech. 2016; 9: 3256-3281.
79. Perdigon G, Galdeano C, Valdez JC et al. Interaction of lactic acid bacteria with the gut immune system. Eur J Clin Nutr. 2002; 56(4): 521-526. Doi: 10.1038/sj.ejcn.1601658.
80. Shi LH, Balakrishnan K, Thiagarajah K et al. Beneficial properties of probiotics. Trop Life Sci Res. 2016; 27(2): 73-90. Doi: 10. 21315/tlsr2016.27.2.6.
81. Halo H, Faye T, Brede DA et al. Bacteriocins of propionibacteria. Lait. 2002; 82: 59-68.
82. Jan G, Leverrier P, Proudi I et al. Survival and beneficial effects of Propionibacteria in the human gut. In vivo and In vito investigations. Lait. 2002; 82: 131-144.
83. Jan G, Belzacq S, Haouzi D et al. Propionibacteria induce apoptosis of colorectal carcinoma cells via. short chain fatty acids acting on mitochondria. Cell Deaths Differ. 2002; 9: 179-188.
84. Leverrier P, Dimova D, Pichereau V et al. Susceptibility and adaptive responses to bile salts in Propionibacterium freuden reichii: Physiological and proteomic analysis. Appl Environ Microbiol. 2003; 69: 309-318.
85. Verobjeva LI, Khodjaev EY and Verobjeva NV. Propioniacid bacteria as probiotics. Microbiol Ecology Health Dis 2008; 20: 109-112
86. Warminska Radiko I, Laniewake-Moro L and Babuchowski A. Influence of propionibacteria on selected pathogenic microorganisms. 3rd International symposium on propionibacteria. Zurich. 2006; 36: 8-11.
87. Motta AS and Brandelli A. Characterization of an antibacterial peptide produced by Brevibacterium linens. J Appl Microbiol. 2002; 92(I): 63-70. Doi:10.1046/j.1365-2672. 2002.01490.
88. Reddy MS. Genesis, evaluation, and progression of a breakthrough discovery to efficiently cure cancer through use of Dr. M.S. Reddy’s Multiple Mixed Strain Probiotics as adjuvants along with the traditional cancer therapies, through restoration of healthy and balanced intestinal microbiota and their microbiome. LOJ Phar Cli Res. 2019; 1(5): 107-109. Doi:10.32474/lo/pcr.2019.01.000121.
2. Reddy MS. Mechanism of Cytokine Storm in COVID-19: How can probiotics combat it? JAAPI. 2021; 1(3): 27-35.
3. Reddy MS. Selected multiphase treatment for coronavirus respiratory infections. US Patent #11,077,052, B1. 2021; 1-38.
4. Li, W., Moore, M. J., Vasilieva, N. et al. Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature. 2003; 426: 450–454. doi: 10.1038/nature02145
5. Li X, Jang Y, Agostin IS, et. al. Is Hydrochloroquine beneficial for Covid -19 patients? Cell Death Dis. 2020; 11: 512. https://doi.org/10.1038/s41419-020-2721-8.
6. Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell 2020; 181: 271–280. doi: 10.1016/j.cell.2020.02.052
7. Kirchdoerfer RN, Cottrell CA, Wang, N, et al. Pre-fusion structure of a human coronavirus spike protein. Nature. 2016; 531: 118–121. doi: 10.1038/nature17200
8. Turner, A. J., Tipnis, S. R., Guy, J. L., et. al. ACEH/ACE2 is a novel mammalian metallocarboxypeptidase and a homologue of angiotensin-converting enzyme insensitive to ACE inhibitors. Can. J. Physiol. Pharmacol. 2002; 80: 346–353. doi: 10.1139/y02-021
9. Yan, R., Zhang, Y., Li, Y., et. Al. Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2. Science. 2020; 367: 1444–1448. doi: 10.1126/science.abb2762
10. Sharma A, Sharma SK, Shi Y, et.al. BCG Vaccination Policy and preventive Chloroquine usage: Do they have an impact on covid -19 pandemic? Cell Death Dis. 2020; 11: 516. https://doi.org/10.1038/s41419-020-2720-9.
11. Verkhratsky A, Li Q, Melino S, et.al. Can COVID -19 pandemic boost the epidemic of Neurogenerative disease? Biol. 2020; Direct 15: 28.
12. Donoghue M, Hsieh F, Baronas E, et al. A novel angiotensin-converting enzyme–related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9. Circul. 2000; Res. 87, e1–e9. doi: 10.1161/01.RES.87.5.e1
13. Celardo I, Pace L, Cifaldi L,. et.al. The immune system view of the Corona Virus SARS – CoV-2. Biol Direct. 2020; 15:30.
14. Krijnse-Locker J, Ericsson M, Rottier P. Characterization of the budding compartment of mouse hepatitis virus: evidence that transport from the RER to the Golgi complex requires only one vesicular transport step. J. Cell Biol. 1994; 124: 55–70. doi: 10.1083/jcb.124.1.55
15. Ghosh S, Dellibovi – Raghes TA, Kerviel A, et.al., β – Coronaviruses use lysosomes for egress instead of the biosynthetic secretory pathway. Cell. 2020; 183(6): 1520-1535.
16. Fehr AR, and Perlman S. Coronaviruses: an overview of their replication and pathogenesis. Coronaviruses. 2015; 1282: 1–23. doi: 10.1007/978-1-4939-2438-7_1
17. Ducatelle R, Hoorens, J. Significance of Lysosomes in the Morphogenesis of Corona Viruses. Arch Viral. 1984; 79: 1-12.
18. Westerbeck JW, Machamer CE. The infectious Bronchitis Corona Virus envelop protein alters Golgi Ph to protect the spike protein and promote the release of infectious virus. J. Virol. 2019; 93: (11): e.000 15-19. Doi: 10. 1128/jvi. 0015-19.
19. Matsuyama MA, Kubil SP, Yoshinaga SK, et al. An Aberrant Stat pathway is central to COVID -19. Cell Death Differ. 2020; 27: 3209-3225.
20. Wang X, Melino G, Shi Y. Active or passively deacidified Lysosomes push β – Corona Virus egress. Cell Death Disease. 2021; 12:235.
21. Agarti C, Sacchi A, Bordoni V, et.al. Expansion of Myeloid derived suppressor cells in patients with severe Corona Virus disease (COVID -19). Cell Death Differ. 2020; 3196 – 3207.
22. Shi Y, Wang Y, Shao C, et.al. COVID -19 infection: The perspective on immune responses. Cell Death Differ. 2020; 27: 1451-1454.
23. Reddy MS. Probiotics: genesis, current definition, and proven therapeutic properties. JAAPI. 2021; l (2): 18-26.
24. Expert consultation on evaluation of health and nutritional properties of probiotics in food including powdered milk with live lactic acid bacteria 2001 (Google scholar). http://www.fao.org/3/a0512e/aO512e.pdf
25. Teame T, Wang A, Xie M, et al. Paraprobiotics and postbiotics of probiotic lactobacilli, their positive effects on the host action mechanism: A review. Front Nutr. 2020; 22: 1-56.
26. Lebeer S, Vanderleyden J, Dekeersmaechker. SCJ. Host interactions of probiotic bacterial surface molecules: comparison with commensals and pathogens. Nat Rev Microbiol 2010; 8: 171-184.
27. Asong J, Wolfert MA, Maiti KK, et al. Binding and cellular activation studies reveal that toll-like receptor-2 can differentially recognize peptidoglycan from gram- positive and gram-negative bacteria. J Biol Chem. 2009; 284: 8643-8653.
28. Shida K, Kiyoshima – Shibata J, Kaji R, et al. Peptidoglycan from lactobacilli inhibits interleukins-12 production by macrophages indued by Lactobacillus casei through toll-like receptor-2 dependent and independent mechanisms. Immunol. 2009; 128: 858-869.
29. Fernandez EM, Valenti R, Rockel C, et al. Anti-inflammatory capacity of selected lactobacilli in experimental colitis is driven by NOD-2-mediated recognition of specific peptidoglycan-derived muropeptide. Gut. 2011; 60: 1050-1059.
30. Noh SY, Kang SS, Yun CH, et al. Lipoteichoic acid from Lactobacillus plantarum inhibits PAM-2 CSK4-induced IL-8 production in human epithelial cells. Mol Immunol. 2015; 64: 183-189.
31. Bleau C, Monges A, Rashidan K, et al. Intermediate chains of exopolysaccharides from Lactobacillus rhamnosus RW-9595 M increases lL-10 production by macrophages. J Appl Microbiol. 2010; 108: 666-675.
32. Murofushi Y, Villena J, Morie K, et al. The toll-like receptor family protein RP105/MDl complex is involved in the immunoregulatory effect of exopolysaccharides from Lactobacillus plantarum N 14. Mol Immunol. 2015; 64: 63-75.
33. Makino S, Ikegami S, Kume A, et al. Reducing the risk of infection in the elderly by dietary intake of yogurt with Lactobacillus delbrueckii ssp. bulgaricus OL L 1073 R-l. Br J Nutr. 2010; 104: 998-1006.
34. Lebeer S, Claes l, Tytgat HLP, et al. Functional analysis of Lactobacillus rhamnosus GG pili in relation to adhesion and immunomodulatory interactions with intestinal epithelial cells. Appl Environ Microbiol. 2012; 78: 185-193.
35. Vargas Garcia CE, Petrova M, Claes IJJ, et al. Piliation of Lactobacillus rhamnosus GG promotes adhesion, Phagocytosis, and cytokine modulation in macrophages. Appl Environ Microbiol. 2015; 81: 2050-2062.
36. Seth A, Yan F, Polk DB, et al. Probiotics ameliorate the hydrogen peroxide -induced epithelial barrier disruption by a PKC-and MAP kinase-dependent mechanism. Am J Physiol Gastrointest liver physiol. 2008; 294: 1060-1070.
37. Herawati I, Hilmiprima D, Fauziah N, Effect of lactic acid filtrate and bacteriocins of Lactobacillus acidophilus on phagocytosis activity of macrophages cell against Enteropathogenic Escherichia coli (EPEC). Microbiol. 2014; 8: 183-190.
38. Pascale A, Marchesi N, Marelli C, et al. Microbiota and metabolic diseases. Endocrine 61: 1357-1371.
39. Smith PM, Howitt MR, Panikov N, et al. Microbial metabolites, short chain fatty acids, regulate colinic t-reg cell homeostasis. Science. 2013; 341: 569-573.
40. Furusawa Y, Yuuki Obata Y, Shinji Fukuda S, et al. Commensal microbiome derived butyrate induces the differentiation of colonic regulatory T-cells. Nature. 2013; 504: 446-450.
41. Roelofsen H, Priebe MG, Vonk RJ, et al. The interaction of short chain fatty acids with adipose tissue: Relevance for prevention of type 2 diabetes. Beneficial microbes. 2010; 1: 433-437.
42. Sun M, Wu W, Chen L, et al. Microbiota derived short chain fatty acids promote TH-l cell lL-10 production to maintain intestinal homeostasis. Nat Commun. 2018; 9: 3555.
43. Reddy MS. Pathophysiology of thrombosis in COVID-19: Possible remedy through Multiple-Mixed-Strain Probiotic Adjuvant therapy. Shusruta medical news AAPI Journal. 2020 https://www.aapiusa.org/wpcontent/uploads/2020/04/sushruta-med-news April 2020.pdf.
44. Baud D, Qi, X, Nielsen-Saines, K, et. al. Real estimates of mortality following COVID-19 infection. Lancet Infect. Dis. 2020. doi: 10.1016/S1473-3099(20)30195-X.
45. Crackower MA, Sarao R, Oudit GY, et al. Angiotensin-converting enzyme 2 is an essential regulator of heart function. Nature. 2002; 417, 822–828. doi: 10.1038/nature00786
46. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 395: 497–506, 2020. doi: 10.1016/S0140-6736(20)30183-5
47. Ramachandran, V., Ismail, P., Stanslas, J., et. al. Association of insertion/deletion polymorphism of angiotensin-converting enzyme gene with essential hypertension and type 2 diabetes mellitus in Malaysian subjects. J. Renin Angiotensin Aldosterone Syst 2008; 9: 208–214. doi: 10.1177/1470320308097499
48. Gustafsson F, and Holstein-Rathlou NH. Angiotensin II modulates conducted vasoconstriction to norepinephrine and local electrical stimulation in rat mesenteric arterioles. Cardiovasc. 1999; Res 44: 176–184. doi: 10.1016/S0008-6363(99)00174-1
49. Watanabe, T., Barker, T. A., and Berk, B. C. Angiotensin II and the endothelium: diverse signals and effects. Hypertension. 2005;45: 163–169. doi: 10.1161/01.HYP.0000153321.13792.b9
50. Senchenkova, E. Y., Russell, J., Almeida-Paula, L. D., et. Al. Angiotensin II–mediated microvascular thrombosis. Hypertension. 2010; 56: 1089–1095. doi: 10.1161/HYPERTENSIONAHA.110.158220
51. Santos, R. A., e Silva, A. C. S., Maric, C., et al. Angiotensin-(1-7) is an endogenous ligand for the G protein-coupled receptor Mas. Proc. Natl. Acad. Sci. U.S.A. 2003; 100: 8258–8263. doi: 10.1073/pnas.1432869100
52. Singh, K. D., and Karnik, S. S. Angiotensin receptors: structure, function, signaling and clinical applications. J. Cell Signal 2016; 1: 111. doi: 10.4172/jcs.1000111
53. Tay, K.-H., and Lip, G. Y. (2 What “Drives” the Link Between the Renin–Angiotensin–Aldosterone System and the Prothrombotic State in Hypertension? Oxford, UK: Oxford University Press, 2008.
54. Zhou, F., Yu, T., Du, R., et.al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020; 395: 1054–1062. doi: 10.1016/S0140-6736(20)30566-3
55. Liu Y, Yu X, Yu L et al. Lactobacillus plantarum CCFM 8610 alleviates irritable bowel syndrome and prevents gut microbiota dysbiosis: a randomized double blind, placebo-controlled pilot clinical trial. Engineering. 2021; 7(3): 376-385.
56. Salva S, Villena J, Alverez S. Immunomodulatory activity of Lactobacillus rhamnosus strain isolated from goat milk: Impact on intestinal and respiratory infections. Int J Food Microbiol. 2010; 141(1-2): 82-89.
57. Klaver FAM, Van der Meer R. The assumed estimation of cholesterol removal by lactobacilli and Bifidobacterium bifidum is due to their bile salt deconjugation activity. Appl Environ Microbiol. 1993; 59: 1120-1124.
58. Borchers AT, Selmi C, Meyers FJ et al. Probiotics and Immunity. J Gastroenterol. 2009; 44: 26-46. Doi:10.1007/s00535-008-2296-0.
59. Brashears MM, Gilliland SE, Buck LM. (1998). Bile salt deconjugation and cholesterol removal from media by Lactobacillus casei. J Dairy Sci. 1998; 81: 2103-2110.
60. Reddy MS. Dr. M.S. Reddy’s Multiple Mixed Strain Probiotic Adjuvant Cancer Therapy, to complement immune checkpoint therapy and other traditional cancer therapies, with least autoimmune side effects through eco-balance of human microbiome. Int J. Pharma Sci Nano Tech. 2018; 11(6): 4295-4317.
61. Sgouras D, Maragkoudakis P, Petraki K et al. In vitro and In vivo inhibition of Helicobacter pylori by Lactobacillus casei strain Shirota. Appl Environ Microbiol. 2004; 70: 518-526. Doi:10.1128/aem.70.1.518-526.
62. Chen Y, Li C, Xue J et al. Characterization of angiotensin-converting enzyme inhibitory activity of fermented milk produced by Lactobacillus helveticus. J Dairy Sci. 2015; 98(8): 5113-5124. https://doi.org/10.3168/jds. 2015-9382.
63. Yamamura S, Morishima H, Kumano-go T et al. The effect of Lactobacillus helveticus fermented milk on sleep and health perception in elderly subjects. Eur J Clinical Nutrition. 2009; 63(1): 100-105.
64. Hosoya T, Sakai F, Yamashita M et al. Lactobacillus helveticus SBT2171 inhibit lymphocyte proliferation by regulation of the JNK signaling pathway. Plos one. 2019; v9(9) e 108-360. https:// doi. Org/10.1371/journal.pone.0108360.
65. Huang R, Wang K, Hu J. Effect of probiotics on depression: A systematic review and meta-analysis of randomized controlled trials. Nutrients. 2016; 8(8): 483. https.//doi.org/10.3390/nu8080483.
66. Liang S, Wang T, Hu X et al. Administration of Lactobacillus helveticus NS8 improves behavioral, cognitive, and biochemical aberrations caused by chronic restraint stress. Neuroscience. 2015; 310: 561-577.
67. Saarela M, Lahteenmaki I, Crittenden R et at. Gut bacteria and health foods-the European perspective. Int J Food Microbiol. 2002; 78: 99-117.
68. Rodriguez C, Medici M, Valdez GF et al. Therapeutic effect of Streptococcus thermophilus CRL-1190-fermented milk on chronic gastritis. World J Gastroenterol. 2010; 16(13): 1622-1630. Doi: 10.3748/wig.v16.i13.1622.
69. Lecomte X, Gagnaire V, Lortal S et al. Streptococcus thermophilus, an emerging and pro liberation of bio peptides from milk for tool for heterologous expression: advantages and future trends. Food Microbiol. 2016; 53: 2-9. Doi: 10.1016/j.bk.2015.05.003.
70. Reddy MS and Reddy DRK. An insight into the 2016 Best Medical Award-Winning Breakthrough Microbial and Nanotechnology based discovery of Dr. M.S. Reddy’s Multiple Mixed Strain Probiotic Therapy, to successfully treat the Nosocomial infections. Nano Technol and Nano Sci. J. 2017; 1(1): 2-5.
71. Tufail M, Hussain S, Malik F et al. Isolation and evaluation of antimicrobial activity of bacteriocin produced by Lactobacillus bulgaricus from yogurt. AFR J Microbiol Res. 2011; 5: 3842-3847.
72. Vacchi ED and Drago L. Lactobacillus sporogenes or Bacillus coagulans; misidentification or mislabeling. Int J Probiotics. 2006; 1: 3-10.
73. Zhang M, Hang X, Fan X et al. Characterization and selection of lactobacillus strains for their effect on bile tolerance, taurocholate deconjugation and cholesterol removal. World J Microbiol Bio Technol. 2008; 24(1): 7-14. Doi.org/10.1007/s11274-007-9431-6.
74. Ahn YT, Kim GB, Lim KS et al. Deconjugation of bile salts by Lactobacillus acidophilus isolates. Int Dairy J. 2003; 13: 300-311.
75. Anderson JW and Gilliland SE. Effect of fermented milk (yogurt) containing lactobacillus acidophilus L1 on serum cholesterol in hypercholesterolemic humans. J AM College Nutr. 1999; 18: 43-50.
76. Nuryshev M, Stoyanova LLG and Netrusov AI. New probiotic culture of Lactococcus lactis ssp. lactis: Effective opportunities and prospects. J Micro Biochem Technol. 2016; 8: 290-295. Doi:10.4172/1948-5948.1000 299.
77. Darby TM, Owens JA, Saeedi BJ et al. Lactobacillus lactis subsp. cremoris is an efficacious beneficial bacterium that limits tissue injury in the intestine. Science. 2019; 12: 356-367. Doi:10.1016/j.IscI.2019.030.
78. Reddy MS and Reddy DRK. Development of Multiple Mixed Strain Probiotics for “Probiotic therapy” under clinical conditions, to prevent or cure the deadly hospital acquired infections due to Clostridium difficile (C. diff) and Methicillin Resistant Staphylococcus aureus (MRSA). Int J Pharma Sci Nanotech. 2016; 9: 3256-3281.
79. Perdigon G, Galdeano C, Valdez JC et al. Interaction of lactic acid bacteria with the gut immune system. Eur J Clin Nutr. 2002; 56(4): 521-526. Doi: 10.1038/sj.ejcn.1601658.
80. Shi LH, Balakrishnan K, Thiagarajah K et al. Beneficial properties of probiotics. Trop Life Sci Res. 2016; 27(2): 73-90. Doi: 10. 21315/tlsr2016.27.2.6.
81. Halo H, Faye T, Brede DA et al. Bacteriocins of propionibacteria. Lait. 2002; 82: 59-68.
82. Jan G, Leverrier P, Proudi I et al. Survival and beneficial effects of Propionibacteria in the human gut. In vivo and In vito investigations. Lait. 2002; 82: 131-144.
83. Jan G, Belzacq S, Haouzi D et al. Propionibacteria induce apoptosis of colorectal carcinoma cells via. short chain fatty acids acting on mitochondria. Cell Deaths Differ. 2002; 9: 179-188.
84. Leverrier P, Dimova D, Pichereau V et al. Susceptibility and adaptive responses to bile salts in Propionibacterium freuden reichii: Physiological and proteomic analysis. Appl Environ Microbiol. 2003; 69: 309-318.
85. Verobjeva LI, Khodjaev EY and Verobjeva NV. Propioniacid bacteria as probiotics. Microbiol Ecology Health Dis 2008; 20: 109-112
86. Warminska Radiko I, Laniewake-Moro L and Babuchowski A. Influence of propionibacteria on selected pathogenic microorganisms. 3rd International symposium on propionibacteria. Zurich. 2006; 36: 8-11.
87. Motta AS and Brandelli A. Characterization of an antibacterial peptide produced by Brevibacterium linens. J Appl Microbiol. 2002; 92(I): 63-70. Doi:10.1046/j.1365-2672. 2002.01490.
88. Reddy MS. Genesis, evaluation, and progression of a breakthrough discovery to efficiently cure cancer through use of Dr. M.S. Reddy’s Multiple Mixed Strain Probiotics as adjuvants along with the traditional cancer therapies, through restoration of healthy and balanced intestinal microbiota and their microbiome. LOJ Phar Cli Res. 2019; 1(5): 107-109. Doi:10.32474/lo/pcr.2019.01.000121.